Ceryx Medical has raised £3.8m in seed funding which will be used to commercialise its technology and commence the first-in-human clinical study of the cardiac rhythm management device, Cysoni, later this year.
The new funding involves Icehouse Ventures, The Development Bank of Wales, Parkwalk Advisors, Business Growth Fund and a consortium of Angel investors.
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. It replicates the natural interaction between heart rate and breathing, prompting the heart to beat as its user breathes, as opposed to the strict ‘metronomic’ beat generated by traditional pacemakers, Ceryx Medical said in a press release.
Stuart Plant, CEO of Ceryx, said: “Our studies have found that Cysoni’s way of pacing the heart increased cardiac output by 20%, when compared with monotonic pacing. The benefits of this for cardiology patients are potentially life-changing and life-extending, because as well as enabling the heart to work more efficiently, Cysoni also repairs the structure of single heart cells. It’s a huge scientific breakthrough.”
“All the signs point to Cysoni being capable of not only making daily life better for those with heart problems, but also of improving the prognosis for even the most seriously ill cardiology patients,” said Plant. “This latest round of funding will enable us to develop our technology for human use and embark on the next phrase of rigorous testing.”
The Ceryx team, alongside scientists from the Universities of Auckland, Bath and Bristol, aims to begin in-human trials in the UK and New Zealand in the final quarter of 2022.